Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Berenson, J. R.
Right arrow Articles by Knight, R. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Berenson, J. R.
Right arrow Articles by Knight, R. D.

Journal of Clinical Oncology, Vol 16, 593-602, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group

JR Berenson, A Lichtenstein, L Porter, MA Dimopoulos, R Bordoni, S George, A Lipton, A Keller, O Ballester, M Kovacs, H Blacklock, R Bell, JF Simeone, DJ Reitsma, M Heffernan, J Seaman and RD Knight
West Los Angeles Veterans Affairs Medical Center and the Jonsson Comprehensive Cancer Center, University of California, 90073, USA. berenson.james@west-la.va.gov

PURPOSE: To determine the efficacy and safety of 21 monthly cycles of pamidronate therapy in patients with advanced multiple myeloma. PATIENTS AND METHODS: Patients with stage III myeloma and at least one lytic lesion received either placebo or pamidronate 90 mg intravenously administered as a 4-hour infusion monthly for 21 cycles. At study entry, the patients were stratified according to whether they were to receive first-line (stratum 1) or second-line (stratum 2) antimyeloma chemotherapy. Skeletal events (pathologic fracture, radiation or surgery to bone, and spinal cord compression) and hypercalcemia were assessed monthly. RESULTS: The results of the first nine previously reported cycles are extended to 21 cycles. Of the 392 randomized patients, efficacy could be evaluated in 198 who received pamidronate and 179 who received placebo. After 21 cycles, the proportion of patients who developed any skeletal event was lower in the pamidronate- group (P = .015). The mean number of skeletal events per year was less in the pamidronate-group (1.3) than in placebo-treated patients (2.2; P = .008). Although survival was not different between the pamidronate- treated group and placebo patients overall, stratum 2 patients who received pamidronate lived longer than those who received placebo (14 v 21 months, P = .041). Pamidronate was safe and well tolerated during the 21 cycles of therapy. CONCLUSION: Long-term monthly infusions of pamidronate as an adjunct to chemotherapy are superior to chemotherapy alone in reducing skeletal events in stage III multiple myeloma patients, and may improve the survival of patients on salvage therapy.


This article has been cited by other articles:


Home page
 BloodHome page
B. Barlogie, F. van Rhee, J. D. Shaughnessy Jr, J. Epstein, S. Yaccoby, M. Pineda-Roman, K. Hollmig, Y. Alsayed, A. Hoering, J. Szymonifka, et al.
Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease
Blood, October 15, 2008; 112(8): 3122 - 3125.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
T. Khong, J. Sharkey, and A. Spencer
The effect of azacitidine on interleukin-6 signaling and nuclear factor-{kappa}B activation and its in vitro and in vivo activity against multiple myeloma
Haematologica, June 1, 2008; 93(6): 860 - 869.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. Raje, S.-B. Woo, K. Hande, J. T. Yap, P. G. Richardson, S. Vallet, N. Treister, T. Hideshima, N. Sheehy, S. Chhetri, et al.
Clinical, Radiographic, and Biochemical Characterization of Multiple Myeloma Patients with Osteonecrosis of the Jaw
Clin. Cancer Res., April 15, 2008; 14(8): 2387 - 2395.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
S. K. Kumar, S. V. Rajkumar, A. Dispenzieri, M. Q. Lacy, S. R. Hayman, F. K. Buadi, S. R. Zeldenrust, D. Dingli, S. J. Russell, J. A. Lust, et al.
Improved survival in multiple myeloma and the impact of novel therapies
Blood, March 1, 2008; 111(5): 2516 - 2520.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
D. Philibert, S. Desmeules, A. Filion, M. Poirier, and M. Agharazii
Incidence and severity of early electrolyte abnormalities following autologous haematopoietic stem cell transplantation
Nephrol. Dial. Transplant., January 1, 2008; 23(1): 359 - 363.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
G. D. Roodman
Skeletal Imaging and Management of Bone Disease
Hematology, January 1, 2008; 2008(1): 313 - 319.
[Abstract] [Full Text] [PDF]

Home page
 JDRHome page
S.L. Ruggiero and S.J. Drew
Osteonecrosis of the Jaws and Bisphosphonate Therapy
Journal of Dental Research, November 1, 2007; 86(11): 1013 - 1021.
[Abstract] [Full Text] [PDF]

Home page
 JDRHome page
D.B. Kimmel
Mechanism of Action, Pharmacokinetic and Pharmacodynamic Profile, and Clinical Applications of Nitrogen-containing Bisphosphonates
Journal of Dental Research, November 1, 2007; 86(11): 1022 - 1033.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
M. T. Petrucci, C. Gallucci, A. Agrillo, M. C. Mustazza, and R. Fo
Role of ozone therapy in the treatment of osteonecrosis of the jaws in multiple myeloma patients
Haematologica, September 1, 2007; 92(9): 1289 - 1290.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
C. Gridelli
The Use of Bisphosphonates in Elderly Cancer Patients
Oncologist, January 1, 2007; 12(1): 62 - 71.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. S. Yeh and J. R. Berenson
Treatment for myeloma bone disease.
Clin. Cancer Res., October 15, 2006; 12(20): 6279s - 6284s.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. P. Grigg, P. Shuttleworth, J. Reynolds, A. P. Schwarer, J. Szer, K. Bradstock, C. Hui, R. Herrmann, and P. R. Ebeling
Pamidronate Reduces Bone Loss after Allogeneic Stem Cell Transplantation
J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 3835 - 3843.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
T. Tanvetyanon and P. J. Stiff
Management of the adverse effects associated with intravenous bisphosphonates
Ann. Onc., June 1, 2006; 17(6): 897 - 907.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
M. Caraglia, D. Santini, M. Marra, B. Vincenzi, G. Tonini, and A. Budillon
Emerging anti-cancer molecular mechanisms of aminobisphosphonates.
Endocr. Relat. Cancer, March 1, 2006; 13(1): 7 - 26.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Badros, D. Weikel, A. Salama, O. Goloubeva, A. Schneider, A. Rapoport, R. Fenton, N. Gahres, E. Sausville, R. Ord, et al.
Osteonecrosis of the Jaw in Multiple Myeloma Patients: Clinical Features and Risk Factors
J. Clin. Oncol., February 20, 2006; 24(6): 945 - 952.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J.-J. Body, T. Facon, R. E. Coleman, A. Lipton, F. Geurs, M. Fan, D. Holloway, M. C. Peterson, and P. J. Bekker
A Study of the Biological Receptor Activator of Nuclear Factor-{kappa}B Ligand Inhibitor, Denosumab, in Patients with Multiple Myeloma or Bone Metastases from Breast Cancer
Clin. Cancer Res., February 15, 2006; 12(4): 1221 - 1228.
[Abstract] [Full Text] [PDF]

Home page
 J Oncol PractHome page
S. Ruggiero, J. Gralow, R. E. Marx, A. O. Hoff, M. M. Schubert, J. M. Huryn, B. Toth, K. Damato, and V. Valero
Practical Guidelines for the Prevention, Diagnosis, and Treatment of Osteonecrosis of the Jaw in Patients With Cancer
J. Oncol. Pract, January 1, 2006; 2(1): 7 - 14.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
L. Gao, H. Deng, H. Zhao, A. Hirbe, J. Harding, L. Ratner, and K. Weilbaecher
HTLV-1 Tax transgenic mice develop spontaneous osteolytic bone metastases prevented by osteoclast inhibition
Blood, December 15, 2005; 106(13): 4294 - 4302.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
E. Terpos and M.-A. Dimopoulos
Myeloma bone disease: pathophysiology and management
Ann. Onc., August 1, 2005; 16(8): 1223 - 1231.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
R. E. Coleman
Bisphosphonates in breast cancer
Ann. Onc., May 1, 2005; 16(5): 687 - 695.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
L. Yin
Chondroitin Synthase 1 Is a Key Molecule in Myeloma Cell-Osteoclast Interactions
J. Biol. Chem., April 22, 2005; 280(16): 15666 - 15672.
[Abstract] [Full Text] [PDF]

Home page
 IBMS BoneKEyHome page
T. Matsumoto and M. Abe
The Importance of Notch Signaling in Myeloma Cell-Osteoclast Interactions
IBMS BoneKEy, February 1, 2005; 2(2): 7 - 10.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
J. E. Brown, R. J. Cook, P. Major, A. Lipton, F. Saad, M. Smith, K.-A. Lee, M. Zheng, Y.-J. Hei, and R. E. Coleman
Bone Turnover Markers as Predictors of Skeletal Complications in Prostate Cancer, Lung Cancer, and Other Solid Tumors
J Natl Cancer Inst, January 5, 2005; 97(1): 59 - 69.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. R. Berenson
Recommendations for Zoledronic Acid Treatment of Patients with Bone Metastases
Oncologist, January 1, 2005; 10(1): 52 - 62.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
R. E. Coleman
Bisphosphonates: Clinical Experience
Oncologist, September 1, 2004; 9(suppl_4): 14 - 27.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
F. Saad
RESPONSE: Re: A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients With Hormone-Refractory Metastatic Prostate Carcinoma
J Natl Cancer Inst, August 4, 2004; 96(15): 1183 - 1184.
[Full Text] [PDF]

Home page
 Palliat MedHome page
Y Saunders, J R Ross, K E Broadley, P M Edmonds, and S Patel
Systematic review of bisphosphonates for hypercalcaemia of malignancy
Palliative Medicine, July 1, 2004; 18(5): 418 - 431.
[Abstract] [PDF]

Home page
 JBJSHome page
C. L. Forthman, B. A. Ponce, and H. J. Mankin
Multiple Myeloma with a Pathologic Fracture During Pregnancy. A Case Report
J. Bone Joint Surg. Am., June 1, 2004; 86(6): 1284 - 1288.
[Full Text] [PDF]

Home page
 The OncologistHome page
J. Berenson and R. Hirschberg
Safety and Convenience of a 15-Minute Infusion of Zoledronic Acid
Oncologist, June 1, 2004; 9(3): 319 - 329.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
E. J. C. Angtuaco, A. B. T. Fassas, R. Walker, R. Sethi, and B. Barlogie
Multiple Myeloma: Clinical Review and Diagnostic Imaging
Radiology, April 1, 2004; 231(1): 11 - 23.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. J. Small, M. R. Smith, J. J. Seaman, S. Petrone, and M. O. Kowalski
Combined Analysis of Two Multicenter, Randomized, Placebo-Controlled Studies of Pamidronate Disodium for the Palliation of Bone Pain in Men With Metastatic Prostate Cancer
J. Clin. Oncol., December 1, 2003; 21(23): 4277 - 4284.
[Abstract] [Full Text] [PDF]

Home page
 Palliat MedHome page
H L Neville-Webbe and R E Coleman
The use of zoledronic acid in the management of metastatic bone disease and hypercalcaemia
Palliative Medicine, September 1, 2003; 17(6): 539 - 553.
[Abstract] [PDF]

Home page
 BMJHome page
J R Ross, Y Saunders, P M Edmonds, S Patel, K E Broadley, and S R D Johnston
Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer
BMJ, August 30, 2003; 327(7413): 469.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Ibrahim, N. Scher, G. Williams, R. Sridhara, N. Li, G. Chen, J. Leighton, B. Booth, J. V. S. Gobburu, A. Rahman, et al.
Approval Summary for Zoledronic Acid for Treatment of Multiple Myeloma and Cancer Bone Metastases
Clin. Cancer Res., July 1, 2003; 9(7): 2394 - 2399.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. H. Ma, H. H. Yang, K. Parker, S. Manyak, J. M. Friedman, C. Altamirano, Z.-q. Wu, M. J. Borad, M. Frantzen, E. Roussos, et al.
The Proteasome Inhibitor PS-341 Markedly Enhances Sensitivity of Multiple Myeloma Tumor Cells to Chemotherapeutic Agents
Clin. Cancer Res., March 1, 2003; 9(3): 1136 - 1144.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
A. Skerjanec, J. Berenson, C. Hsu, P. Major, W. H. Miller Jr., C. Ravera, H. Schran, J. Seaman, and F. Waldmeier
The Pharmacokinetics and Pharmacodynamics of Zoledronic Acid in Cancer Patients with Varying Degrees of Renal Function
J. Clin. Pharmacol., February 1, 2003; 43(2): 154 - 162.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin. Proc.Home page
D. Saghafi
Use of Bisphosphonates in Patients With Myeloma and Renal Failure
Mayo Clin. Proc., January 1, 2003; 78(1): 118 - 118.
[PDF]

Home page
 The OncologistHome page
M. H. Cohen, R. Dagher, D. J. Griebel, A. Ibrahim, A. Martin, N. S. Scher, G. H. Sokol, G. A. Williams, and R. Pazdur
U.S. Food and Drug Administration Drug Approval Summaries: Imatinib Mesylate, Mesna Tablets, and Zoledronic Acid
Oncologist, October 1, 2002; 7(5): 393 - 400.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
J. Wood, K. Bonjean, S. Ruetz, A. Bellahcene, L. Devy, J. M. Foidart, V. Castronovo, and J. R. Green
Novel Antiangiogenic Effects of the Bisphosphonate Compound Zoledronic Acid
J. Pharmacol. Exp. Ther., September 1, 2002; 302(3): 1055 - 1061.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. R. Berenson, B. E. Hillner, R. A. Kyle, K. Anderson, A. Lipton, G. C. Yee, and J. S. Biermann
American Society of Clinical Oncology Clinical Practice Guidelines: The Role of Bisphosphonates in Multiple Myeloma
J. Clin. Oncol., September 1, 2002; 20(17): 3719 - 3736.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin. Proc.Home page
S. V. Rajkumar, M. A. Gertz, R. A. Kyle, P. R. Greipp, and Mayo Clinic Myeloma, Amyloid, and Dysproteinemia G
Current Therapy for Multiple Myeloma
Mayo Clin. Proc., August 1, 2002; 77(8): 813 - 822.
[Abstract] [PDF]

Home page
 JCOHome page
H. D. Menssen, A. Sakalova, A. Fontana, Z. Herrmann, C. Boewer, T. Facon, M. R. Lichinitser, C.R.J. Singer, L. Euller-Ziegler, M. Wetterwald, et al.
Effects of Long-Term Intravenous Ibandronate Therapy on Skeletal-Related Events, Survival, and Bone Resorption Markers in Patients With Advanced Multiple Myeloma
J. Clin. Oncol., May 1, 2002; 20(9): 2353 - 2359.
[Abstract] [Full Text] [PDF]

Home page
 CA Cancer J ClinHome page
A. A. Zaidi and D. H. Vesole
Multiple Myeloma: An Old Disease with New Hope for the Future
CA Cancer J Clin, September 1, 2001; 51(5): 273 - 285.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. M. Ali, F. J. Esteva, G. Hortobagyi, H. Harvey, J. Seaman, R. Knight, L. Costa, and A. Lipton
Safety and Efficacy of Bisphosphonates Beyond 24 Months in Cancer Patients
J. Clin. Oncol., July 15, 2001; 19(14): 3434 - 3437.
[Abstract] [Full Text] [PDF]

Home page
 Palliat MedHome page
L Groff, E Zecca, F De Conno, C Brunelli, R Boffi, C Panzeri, M Cazzaniga, and C Ripamonti
The role of disodium pamidronate in the management of bone pain due to malignancy
Palliative Medicine, June 1, 2001; 15(4): 297 - 307.
[Abstract] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
G. S. MARKOWITZ, G. B. APPEL, P. L. FINE, A. Z. FENVES, N. R. LOON, S. JAGANNATH, J. A. KUHN, A. D. DRATCH, and V. D. D'AGATI
Collapsing Focal Segmental Glomerulosclerosis Following Treatment with High-Dose Pamidronate
J. Am. Soc. Nephrol., June 1, 2001; 12(6): 1164 - 1172.
[Abstract] [Full Text]

Home page
 The OncologistHome page
R. A. Kyle
Update on the Treatment of Multiple Myeloma
Oncologist, April 1, 2001; 6(2): 119 - 124.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
J. R. Berenson, R. A. Vescio, L. S. Rosen, J. M. VonTeichert, M. Woo, R. Swift, A. Savage, E. Givant, M. Hupkes, H. Harvey, et al.
A Phase I Dose-ranging Trial of Monthly Infusions of Zoledronic Acid for the Treatment of Osteolytic Bone Metastases
Clin. Cancer Res., March 1, 2001; 7(3): 478 - 485.
[Abstract] [Full Text]

Home page
 JCOHome page
P. Major, A. Lortholary, J. Hon, E. Abdi, G. Mills, H. D. Menssen, F. Yunus, R. Bell, J. Body, E. Quebe-Fehling, et al.
Zoledronic Acid Is Superior to Pamidronate in the Treatment of Hypercalcemia of Malignancy: A Pooled Analysis of Two Randomized, Controlled Clinical Trials
J. Clin. Oncol., January 15, 2001; 19(2): 558 - 567.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
R. E. Coleman
Management of Bone Metastases
Oncologist, December 1, 2000; 5(6): 463 - 470.
[Abstract] [Full Text]

Home page
 BloodHome page
N. Raje and K. C. Anderson
Introduction: the evolving role of bisphosphonate therapy in multiple myeloma
Blood, July 15, 2000; 96(2): 381 - 383.
[Full Text] [PDF]

Home page
 BloodHome page
V. Kunzmann, E. Bauer, J. Feurle, F. W.{b.}i. H.-P. Tony, and M. Wilhelm
Stimulation of gamma delta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma
Blood, July 15, 2000; 96(2): 384 - 392.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
R. A. Kyle
The Role of Bisphosphonates in Multiple Myeloma
Ann Intern Med, May 2, 2000; 132(9): 734 - 736.
[Full Text] [PDF]

Home page
 JCOHome page
B. E. Hillner, J. N. Ingle, J. R. Berenson, N. A. Janjan, K. S. Albain, A. Lipton, G. Yee, J. S. Biermann, R. T. Chlebowski, and D. G. Pfister
American Society of Clinical Oncology Guideline on the Role of Bisphosphonates in Breast Cancer
J. Clin. Oncol., March 13, 2000; 18(6): 1378 - 1391.
[Abstract] [Full Text] [PDF]

Home page
 ASH Education BookHome page
K. C. Anderson, R. A. Kyle, W. S. Dalton, T. Landowski, K. Shain, R. Jove, L. Hazlehurst, and J. Berenson
Multiple Myeloma: New Insights and Therapeutic Approaches
Hematology, January 1, 2000; 2000(1): 147 - 165.
[Abstract] [Full Text] [PDF]

Home page
 CLIN PEDIATRHome page
T. Srivastava and U. S. Alon
Bisphosphonates: From Grandparents to Grandchildren
Clinical Pediatrics, November 1, 1999; 38(12): 687 - 702.
[Abstract] [PDF]

Home page
 ANN INTERN MEDHome page
J. L. Abrahm and for the ACP-ASIM End-of-Life Care Consensus Panel
Management of Pain and Spinal Cord Compression in Patients with Advanced Cancer
Ann Intern Med, July 6, 1999; 131(1): 37 - 46.
[Abstract] [Full Text] [PDF]

Home page